Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
8- 9.10After-hours26.09.11 06:07SCHEDULE 13D/AOwnership#●●●
Braveheart Bio, Inc.
OrbiMed Advisors LLC and its affiliates have filed a joint Schedule 13D/A amendment regarding their holdings in Braveheart Bio, Inc. common stock. This filing formalizes the joint filing agreement for the disclosure dated September 8, 2026.…more
$21.38+0.05%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.8After-hours26.09.09 05:0810-QEarnings
Braveheart Bio, Inc.
Braveheart Bio, Inc. has filed its financial results for the second quarter of 2026. As of September 3, 2026, the company had 90,038,969 shares of common stock outstanding.…more
$21.38+0.05%vs prev closeView filingShare - 9.8After-hours26.09.09 05:068-KKey event
Braveheart Bio, Inc.
Braveheart Bio reported its financial results for the second quarter of 2026 and provided an update on its lead clinical candidate, BHB-1893. Following its August 2026 IPO, the company secured approximately $404.5 million in net proceeds, bringing its pro-forma cash and cash equivalents to approximately $527.3 million, which is expected to fund operations into 2029.…more
$21.38+0.05%vs prev closeView filingShare
7 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 9.16After-hours26.09.17 05:30#●●●#●●●
Braveheart Bio to Participate in Stifel Cardiometabolic Forum
Braveheart Bio announced its participation in the upcoming Stifel Virtual Cardiometabolic Forum on September 30. Management will engage in a fireside chat to discuss the company's progress in developing therapeutics for cardiovascular diseases.…more
$21.38+0.05%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 9.8After-hours26.09.09 05:37
●●●●●●●● ●●●●● ●●●●●●
Braveheart Bio reported a quarterly loss per share of $2.51, significantly missing analyst expectations. This result represents a substantial increase in losses compared to the same period last year.…more
$21.38+0.05%vs prev closeShareBenzinga - 9.8After-hours26.09.09 05:03
●●●●●●●● ●●●●● ●●●●●●
Braveheart Bio reported a net loss of $15 million for the second quarter as R&D expenses increased to support its clinical programs. The company is currently advancing its Phase 3 trials for BHB-1893 and expects its IPO proceeds to fund operations through 2029.…more
$21.38+0.05%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report